Institutional Owners May Ignore Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Recent US$67m Market Cap Decline as Longer-term Profits Stay in the Green
Institutional Owners May Ignore Black Diamond Therapeutics, Inc.'s (NASDAQ:BDTX) Recent US$67m Market Cap Decline as Longer-term Profits Stay in the Green
Key Insights
主要見解
- Significantly high institutional ownership implies Black Diamond Therapeutics' stock price is sensitive to their trading actions
- A total of 4 investors have a majority stake in the company with 53% ownership
- Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
- 由機構持有比例高可意味着Black Diamond Therapeutics的股價容易受到他們交易行動的影響。
- 總共有4個投資者持有該公司的53%的所有權。
- 所有權研究和分析師預測數據有助於更好地了解股票市場的機會。
To get a sense of who is truly in control of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), it is important to understand the ownership structure of the business. We can see that institutions own the lion's share in the company with 68% ownership. Put another way, the group faces the maximum upside potential (or downside risk).
爲了真正了解Black Diamond Therapeutics,Inc. (NASDAQ:BDTX)到底由誰掌控,了解該企業的所有權結構就顯得尤爲重要。我們可以看到,機構擁有公司68%的股權。換句話說,該機構面臨的上行潛力(或下跌風險)最大。
Institutional investors endured the highest losses after the company's market cap fell by US$67m last week. However, the 42% one-year return to shareholders may have helped lessen their pain. But they would probably be wary of future losses.
上週公司市值減少了6700萬美元,機構投資者承受了最大的損失。然而,股東們獲得的42%的年回報率可能有助於減輕他們的痛苦。但他們可能會擔心未來的損失。
In the chart below, we zoom in on the different ownership groups of Black Diamond Therapeutics.
在下圖中,我們放大了Black Diamond Therapeutics的不同所有權群體。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240809/0-e7d70262d7359efd3be7223a75ff3bb9-0-7594dfa9b15003d8d8ae04bf2bdd74a3.png/big)
What Does The Institutional Ownership Tell Us About Black Diamond Therapeutics?
機構持股告訴我們Black Diamond Therapeutics的什麼信息?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。
Black Diamond Therapeutics already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Black Diamond Therapeutics' historic earnings and revenue below, but keep in mind there's always more to the story.
Black Diamond Therapeutics已經有機構股東了。實際上,他們在公司中擁有可觀的持股。這表明在專業投資者中具有一定的信譽。但我們不能單純依靠這一事實,因爲機構有時也會犯投資錯誤,就像其他人一樣。當多個機構擁有一隻股票時,總會存在他們會開展一項「擁擠交易」的風險。當這種買賣出現問題時,多個股東可能會競相快速賣出股票。在一家歷史悠久但沒有增長曆史的公司中,這種風險更大。您可以在下面查看Black Diamond Therapeutics的歷史收益和營業收入,但請記住,事情並不總是如此簡單。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240809/0-e7d70262d7359efd3be7223a75ff3bb9-1-ebe00b8287d8a312e5ae9400b0b59a0a.png/big)
Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Black Diamond Therapeutics is not owned by hedge funds. T. Rowe Price Group, Inc. is currently the company's largest shareholder with 19% of shares outstanding. In comparison, the second and third largest shareholders hold about 15% and 11% of the stock.
機構投資者擁有超過50%的股權,因此他們共同可能會強烈影響董事會的決策。Black Diamond Therapeutics沒有由對沖基金擁有。Rowe Price Group, Inc.目前是公司最大的股東,其持有公司19%的流通股。相比之下,第二大和第三大股東分別持有該公司大約15%和11%的股份。
Our research also brought to light the fact that roughly 53% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.
通常是個人投資者的大衆持有滬硅產業股份有限公司22%的股份。儘管持有規模很大,但如果決策不與其他大股東協調,這也許還不足以改變公司的政策。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.
研究機構持股比例是衡量和篩選股票預期表現的好方法。同樣可以通過研究分析師情緒來實現。由於相當多的分析師都關注着該股票,因此你可以很容易地研究預測的增長。
Insider Ownership Of Black Diamond Therapeutics
Black Diamond Therapeutics的內部股權掌握情況
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.
內部人員的定義在不同國家之間可能略有不同,但董事會成員始終計數。公司管理層回答董事會,在此應代表股東利益。值得注意的是,有時高級管理人員也在董事會上。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。
We can report that insiders do own shares in Black Diamond Therapeutics, Inc.. In their own names, insiders own US$5.9m worth of stock in the US$258m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.
我們可以報告內部人員確實擁有Black Diamond Therapeutics,Inc.的股份。在他們自己的名下,內部人員在這家價值25800萬美元的公司中擁有590萬美元的股票。有人會說,這表明股東和董事會之間存在利益一致性。但值得檢查的是,這些業內人士是否一直在出售股份。
General Public Ownership
一般大衆所有權
The general public-- including retail investors -- own 10% stake in the company, and hence can't easily be ignored. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
普通公衆(包括散戶投資者)擁有該公司10%的股份,因此不能被忽視。儘管該集團不能直接發號施令,但它確實對公司的運作產生了實質性影響。
Private Equity Ownership
股權投資公司持有8.8%的股份,有能力參與塑造以價值創造爲重點的公司策略。一些投資者可能會因此而受到鼓舞,因爲股權投資公司有時可以鼓勵市場看到公司的價值,從而採取有益的策略。另外,那些持有者可能在將其上市後退出投資。
Private equity firms hold a 19% stake in Black Diamond Therapeutics. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
股權投資公司持有Black Diamond Therapeutics的19%股權。這表明他們可以在重要的政策決策中發揮影響力。一些投資者可能會因此感到鼓舞,因爲私人股權投資公司有時能夠鼓勵採取能夠使市場看到公司價值的策略。或者,這些持有人可能會在將其上市後退出投資。
Next Steps:
下一步:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Like risks, for instance. Every company has them, and we've spotted 5 warning signs for Black Diamond Therapeutics (of which 2 make us uncomfortable!) you should know about.
我認爲查看公司的實際股權掌控者確實很有趣。但爲了真正獲得見解,我們還需要考慮其他信息。例如風險。每家公司都有風險,我們已經發現了Black Diamond Therapeutics的5個警示信號(其中2個讓我們不安!),您應該了解。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。